Combination therapy comprising an MMP-14 binding protein

1. A method for treating a cancer, the method comprising: 1) identifying a subject as being in need of reducing a side effect of a chemotherapeutic agent, wherein the side effect comprises weight loss; and 2) administering to the subject identified in step 1) an MMP-14 binding protein in combination with at least one additional chemotherapeutic agent, wherein the MMP-14 binding protein is an antibody comprising a heavy chain variable domain of SEQ ID NO: 51 and a light chain variable domain of SEQ ID NO: 52; and wherein the cancer is a melanoma, a pancreatic cancer, or a cancer associated with inappropriate angiogenesis.

2. The method of claim 1 , wherein the MMP-14 binding protein is administered prior to, during, or following administration of the at least one additional chemotherapeutic agent.

3. The method of claim 1 , wherein the cancer is a melanoma.

4. The method of claim 1 , wherein the cancer is a metastatic cancer.

5. The method of claim 1 , wherein the MMP-14 binding protein is capable of binding to tumor cells or tumor tissues expressing MMP-14.

6. The method of claim 1 , wherein the MMP-14 binding protein inhibits MMP-14 activity.

7. The method of claim 1 , wherein the subject comprises tumor cells expressing MMP-14.

8. The method of claim 7 , further comprising measuring the level of MMP-14 in a biopsy sample obtained from the subject.

9. The method of claim 1 , wherein the chemotherapeutic agent is dacarbazine, paclitaxel, or gemcitabine.

10. The method of claim 1 , wherein the cancer is a pancreatic cancer.

11. The method of claim 1 , wherein the cancer is associated with inappropriate angiogenesis.

12. The method of claim 1 , wherein the chemotherapeutic agent is gemcitabine, and wherein the cancer is associated with inappropriate angiogenesis.

13. The method of claim 1 , wherein the MMP-14 binding protein is administered at a dose between 5 mg/kg and 50 mg/kg.

14. The method of claim 1 , wherein the MMP-14 binding protein is administered at a dose between 10 mg/kg and 25 mg/kg.

15. The method of claim 1 , wherein the MMP-14 binding protein is administered in combination with dacarbazine to treat a melanoma.

16. The method of claim 15 , wherein the dacarbazine is administered at a dose of 4.5 mg/kg/day or less.

17. The method of claim 1 , wherein the MMP-14 binding protein is administered in combination with paclitaxel to treat a melanoma.

18. The method of claim 17 , wherein the paclitaxel is administered at a dose of 175 mg/m 2 or less.

19. The method of claim 1 , wherein the MMP-14 binding protein is administered in combination with gemcitabine to treat a pancreatic cancer.

20. The method of claim 19 , wherein the gemcitabine is administered at a dose of 1000 mg/m 2 or less.

21. The method of claim 1 , wherein the MMP-14 binding protein is an IgG.

22. The method of claim 1 , wherein the MMP-14 binding protein is an IgG1.

23. The method of claim 1 , wherein the side effect further comprises inability to thrive.

24. The method of claim 1 , wherein the cancer is a chemotherapeutic sensitive, chemotherapeutic refractory, chemotherapeutic resistant, or relapsed cancer.

25. The method of claim 1 , wherein the cancer is a melanoma and is sensitive, refractory, or resistant to an alkylating agent, a taxane, or an interleukin.

26. The method of claim 25 , wherein the alkylating agent is cyclophosphamide, dacarbazine, melphalan, ifosfamide, or temozolomide.

27. The method of claim 25 , wherein the taxane is docetaxel, paclitaxel, larotaxel, or cabazitaxel.

28. The method of claim 25 , wherein the interleukin is interleukin-2.

29. The method of claim 1 , wherein the cancer is a pancreatic cancer and is sensitive, refractory, or resistant to an anti-metabolite.

30. The method of claim 29 , wherein the anti-metabolite is an antifolate or a pyrimidine analog.

31. The method of claim 30 , wherein the antifolate is pemetrexed, floxuridine, or raltitrexed.

32. The method of claim 30 , wherein the pyrimidine analog is capecitabine, cytarabine, gemcitabine, or 5-fluorouracil.

33. The method of claim 1 , wherein the chemotherapeutic agent is an anti-metabolite.

34. The method of claim 33 , wherein the anti-metabolite is a pyrimidine analog.

35. The method of claim 34 , wherein the pyrimidine analog is gemcitabine.